Wilson Disease Drugs Market Expected to Reach $848.2 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Wilson Disease Drugs Market," The wilson disease drugs market size was valued at $595.17 million in 2021, and is estimated to reach $848.2 million by 2031, growing at a CAGR of 3.6% from 2022 to 2031.

Wilson disease is an inherited disorder in which excessive amounts of copper accumulate in the body, particularly in the liver, brain, and eyes. The signs and symptoms of Wilson disease usually first appear between the ages of 5 and 38, but they most often begin during the teenage years. The features of this condition include a combination of liver disease and neurological and psychiatric problems.

Liver disease is typically the initial feature of Wilson disease in affected children and young adults; individuals diagnosed at an older age usually do not have symptoms of liver problems, although they may have very mild liver disease. The signs and symptoms of liver disease include yellowing of the skin or whites of the eyes (jaundice), fatigue, loss of appetite, and abdominal swelling.

Nervous system or psychiatric problems are often the initial features in individuals diagnosed in adulthood and commonly occur in young adults with Wilson disease. Signs and symptoms of these problems can include clumsiness, tremors, difficulty walking, speech problems, impaired thinking ability, depression, anxiety, and mood swings. In many individuals with Wilson disease, copper deposits in the front surface of the eye (The cornea) form a green-to-brownish ring, called the Kayser-Fleischer ring, that surrounds the colored part of the eye. Abnormalities in eye movements, such as a restricted ability to gaze upwards, may also occur.

The key factors that drive the growth of wilson disease drugs market size is increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. Moreover, increase in investmentby players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure are further expected to boost the wilson disease drugs industry growth during forecast period. However, high treatment cost due to complications is likely to hamper the growth of the Wilson disease drugs market during the forecast period. Conversely, high investment by the government for drug development and increase in healthcare expenditure are expected to provide numerous opportunities for market growth during the forecast period.

By drug type, the Penicillamine segment dominated the wilson disease drugs market share in 2021 and is expected to remain dominant during the forecast period, owing to increase in prevalence of Wilson disease. In addition, penicillamine binds to copper and helps it to be removed from the body. Decreasing copper levels helps to improve liver function and the mental/mood/nerve problems (such as confusion, difficulty speaking/walking) caused by the disease further boost the wilson disease drugs market trends.

By distribution channel, the retail pharmacies segment dominated the wilson disease drugs market share in 2021 and is expected to remain dominant during the forecast period, owing to increase in Wilson disease patients, the growing number of independent pharmacies and chains along with the availability of medications in supermarkets & mass retailers in countries, such as the U.S. and UK. In addition, the presence of large chains, such as CVS Health, Boots Walgreens, Shoppers Drug Mart, Lloyd, and Well pharmacy, in a few countries, such as the U.S., Canada, the U.K., Australia, and Russia Further propel the market growth. Moreover, the rapid adoption of automation technologies, such as pharmacy robots, dispensing, and packaging systems is driving the segment growth.

Region wise, wilson disease drugs market analysis across North America, Europe, asia-Pacific and LAMEA. North America has the highest market share, with $251.28 million in 2021, registering a CAGR of 2.2% during the forecast period. Owing to the investments  made by the key players for various R&D activities as well as launch of new products in the U.S. In addition, increase awareness among the consumers for the adoption of Wilson disease drugs is further anticipated to stimulate the growth of the Wilson disease drugs industry in North America. Asia pacific is projected to register the highest CAGR of 5.5% during the wilson disease drugs market forecast period. The evolving healthcare regulatory landscape, an increase in the number of patients with Wilson diseases, and the government's emphasis on enhancing R&D capabilities for innovative drug development are the key driving factors that boost the growth of the market in the region.

Key findings of the study

• On the basis of drug type, the penicillamine segment dominated the market in 2021 and is expected to continue this trend during the forecast period.

• Depending on distribution channel, retail pharmacies segment is projected to grow at a CAGR of 2.2% during the forecast period.

• Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 5.5% during the forecast period.